Braveheart Bio/$BRVE

1D1W1MYTD1Y5YMAX

About Braveheart Bio

Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases. Its flagship product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).
Ticker
$BRVE
Sector
Health
Primary listing
NASDAQ
Employees
49
Headquarters
San Francisco, United States
Website
www.braveheart.bio

Braveheart Bio Metrics

BasicAdvanced
$1.9B
-
-$14.68
-
-

Bulls say / Bears say

In March 2026, Braveheart Bio and Hengrui Pharma announced Phase 2 obstructive HCM results showing BHB-1893 yielded rapid, substantial reductions in left ventricular outflow tract gradients with a favorable safety profile in obstructive HCM patients (PRNewswire)
In May 2026, a randomized, placebo-controlled Phase 2 trial of BHB-1893 in non-obstructive HCM demonstrated rapid and sustained improvements in cardiac structure, diastolic function, biomarkers, and symptoms, suggesting a potential disease-modifying therapy (PRNewswire)
In August 2026, Jefferies initiated coverage on Braveheart Bio with a Buy rating and a $48.00 price target, and Goldman Sachs followed with a Buy rating and a $48.00 price target, reflecting strong institutional confidence in BHB-1893’s clinical differentiation and commercial potential (Investing.com, Investing.com)
Braveheart Bio is wholly dependent on BHB-1893 for its future prospects, and failure to demonstrate sufficient efficacy or safety in pivotal trials would have a material adverse effect on its business and prospects (SEC Filing)
Cytokinetics’ MYQORZO (aficamten) received FDA approval in December 2025 and launched commercially in Q1 2026, establishing a first-mover advantage and commercial presence in obstructive HCM ahead of BHB-1893 (Cytokinetics IR)
As of April 29, 2026, Braveheart Bio’s cash and cash equivalents are sufficient to fund operations for only the next twelve months, necessitating additional fundraising to complete global Phase 3 trials and risking dilution for shareholders (SEC Filing)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2026.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.